SEPTEMBER/OCTOBER

Vol 9, No 5 CME Pretest

This Journal provides 4 hours of Category 1 Continuing Medical Education

Complimentary CME Credits

Physicians can earn 4 credit hours of Category 1 for the Physician's Recognition Award of the American Medical Association by reading the material in this issue and successfully answering the questions in the posttest at the end of this issue. Complete instructions are given on the posttest pages. Successfully answering 30 or more questions will earn 4 credit hours.

Educational Objectives

After reading this issue of Cancer Control, clinicians will be expected to:

• discuss the roles of molecular genetics and laser therapy in managing localized head and neck cancer,

• prescribe treatment for locally advanced head and neck cancers and identify and manage dysphagia as a consequence of treatment,

• integrate the principles of ethical decision making in cancer management,

• recognize the benefits of once-daily aminoglycoside administration for neutropenic fever, and

• appreciate the clinical pathologic features of retroperitoneal fibrosis.

This program was planned in accordance with ACCME Essentials.

Release Date: September 1, 2002
Expiration Date: September 1, 2003

1. What additional intervention is used to minimize scarring after laser resection of tumors of the floor of the mouth and inferior surface of the mobile tongue?

a. radiation
b. skin grafts
c. antibiotics
d. vitamins

 

2. Posner et al have reported increased response rates of advanced squamous cell head and neck cancer by adding which drug to a combination of cisplatin plus 5-fluorouracil?

a. mitomycin C
b. paclitaxel
c. docetaxel
d. gemcitabine

 

3. What characteristic of aminoglycoside treatment is associated with an increased incidence of nephrotoxicity?

a. elevated peak levels
b. increased trough levels
c. once-daily dosing
d. combinations with β-lactam antibiotics